Compare Repligen Corporation Common Stock (RGEN) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs AT&T Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while AT&T Inc. trades at $23.28 (market cap $157.95B). The key difference: AT&T Inc. is far larger — about 14× Repligen Corporation Common Stock's market cap, and AT&T Inc. pays a 4.82% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| RGEN | T | |
|---|---|---|
Market Cap | $11.31B | $157.95B |
Volume | 1,216,919 | 40,269,473 |
Sector | Health | Media |
52-Week High | $194.57 | $29.10 |
52-Week Low | $102.87 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $11.20B | $303.27B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
AT&T (T) trades at $22.86, up 1.65% today, showing strong fundamental performance with a low P/E of 7.54 and robust profitability metrics including 16.94% net margin. The company has beaten earnings estimates for three consecutive quarters and maintains solid cash flow generation of $15.12B in 2025. Technical indicators show mixed signals with bearish moving averages but bullish oscillators, while analyst consensus remains divided with a $27.39 price target.
The stock presents value investment characteristics with attractive valuation multiples and consistent dividend payments. Key opportunities include fiber expansion initiatives and wireless growth, while risks center on heavy debt load and competitive pressures. The current price near support levels offers potential upside to analyst targets, though technical weakness requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
